$B9V1i(B $B;~9o(B | $B9V1i(B $BHV9f(B | $B9V1iBjL\!?H/I=$B%-!<%o!<%I(B | $BJ,N`(B $BHV9f(B | $B$BHV9f(B | |
L$B2q>l(B |
(9:30$B!A(B10:45) ($B:BD9(B $BD9;3(B $BOB;K!&CfB<(B $B=(H~(B) |
9:30$B!A(B 9:45 | L01 | $B%R%H%K%e!<%m%F%s%7%s
($B?@8MBg9)(B) $B!{66(B $B90$B!&(B ($B?@8MBg1!9)(B) ($B@5(B)$BCfB<(B $BBYG7(B$B!&(B ($B?@8MBg8&5f4D(B) ($B@5(B)$B@P0f(B $B=c(B$B!&(B ($B?@8MBg1!9)(B) ($B@5(B)$B6aF#(B $B> | GPCR Yeast-based biosensor Ligand screening
| 7-e | 117 |
9:45$B!A(B 10:00 | L02 | $BC44b%^%&%9$X$N(BTi$B%J%NN3;REjM?$K$h$k@8BNFbJ,I[(B
($B?@8MBg(B) $B!{NkLZ(B $B5.90(B$B!&(B $BEDLn(B $B0!ETN$(B$B!&(B ($B3X(B)$B?9ED(B $B7rB@(B$B!&(B ($B@5(B)$B2.Ln(B $B@i=)(B$B!&(B ($B@5(B)$B6aF#(B $B> | Titanium nano particles mouse biodistribution
| 7-e | 103 |
10:00$B!A(B 10:15 | L03 | $BE|!<%k7OG[0L;R$N9g@.$H%$%*%sJaB*G=(B
($BJF;R9b@l(B) $B!{C]B<(B $BM451(B$B!&(B ($B@5(B)$Bdk4V(B $BM39,(B | Ligand Sugar Complex
| 7-e | 19 |
10:15$B!A(B 10:30 | L04 | $BE|
($BJF;R9b@l(B) $B!{Ln!9B<(B $BBsLi(B$B!&(B ($B@5(B)$Bdk4V(B $BM39,(B$B!&(B $BFbF#(B $B@12B(B$B!&(B ($BD;.>B(B $BK.=E(B$B!&(B $B2,ED(B $BB@(B | photodynamic Therapy cancer
| 7-e | 35 |
10:30$B!A(B 10:45 | L05 | $B%$%*%s1UBN$K$h$k7PHi?;F)B%?J8z2L$rMxMQ$7$??75,7PHi%o%/%A%s@=:^$N3+H/(B
($B6eBg(B) $B!{9SLZ(B $B>MB@(B$B!&(B ($B3X(B)$B@nO2(B $BBn;N(B$B!&(B ($B@5(B)$B$B!&(B ($B@5(B)$B?@C+(B $BE5Jf(B$B!&(B ($B@5(B)$B8eF#(B $B2m9((B | Ionic Liquid Transdermal drug delivery Vaccine
| 7-e | 102 |
(10:45$B!A(B12:00) ($B:BD9(B $B5HED(B $B7r!&>.@n(B $B0!4u;R(B) |
10:45$B!A(B 11:00 | L06 | $BAB?e@-%3%"Fb$NAj8_:nMQ$rMxMQ$7$??75,N>?FG^@-%Z%W%A%I=89gBN$NAO@=(B
($B6eBg(B) $B!{66K\(B $BN60lO/(B$B!&(B ($B@5(B)$B$B!&(B ($B@5(B)$B8eF#(B $B2m9((B$B!&(B ($B@5(B)$B?@C+(B $BE5Jf(B | peptide amphiphiles self-assembly
| 7-e | 51 |
11:00$B!A(B 11:15 | L07 | Solid-in-Oil$B2=5;=Q$rMxMQ$7$?9386%Z%W%A%I$N7PHi%G%j%P%j!<$K$h$k$,$s%o%/%A%s8z2L(B
($B6eBg(B) $B!{:yLZ(B $BM%?M(B$B!&(B ($B3X(B)$BJ?@n(B $BM4Li(B$B!&(B ($B@5(B)$B$B!&(B ($B@5(B)$B?@C+(B $BE5Jf(B$B!&(B ($B@5(B)$B8eF#(B $B2m9((B | Transdermal drug delivery system Cancer vaccine Solid-in-oil (S/O) dispersion
| 7-e | 67 |
11:15$B!A(B 11:30 | L08 | $BHs%$%*%s3&LL3h@-:^$NE:2C$K$h$jM6F3$5$l$k:YK&KlJQ2=$N4Q;!(B
($BF`NI9b@lJ*>K\(B $BL@F|9a(B$B!&(B ($B@5(B)$BNS(B $B7$B!&(B ($B@5(B)$BCfB<(B $B=(H~(B | Plasma membrane Vesicle Cytotoxicity
| 7-e | 112 |
11:30$B!A(B 11:45 | L09 | $B5$AjN.DL7?9ZAGH?1~$NH?1~>r7o(B
($B9bCN9b@lJ*$B!&(B ($B@5(B)$BD9;3(B $BOB;K(B | Gas Phase Enzyme Reaction Reaction Conditions
| 7-a | 39 |
11:45$B!A(B 12:00 | L10 | $B%+%$%3$NBN$H;e$N@.J,$G$"$k%?%s%Q%/
($BEg:,8)N)1WED9b(B) $B!{J!K~(B $BOB(B | silkworm pigment fluorescence
| 7-b | 76 |
(13:00$B!A(B14:15) ($B:BD9(B $B |
13:00$B!A(B 13:15 | L11 | PANC-1$B$H(BHepG2$B$N0!1t46
($BNk9b@l(B) $B!{:Y@n(B $B5.;K(B$B!&(B ($B@5(B)$B>.@n(B $B0!4u;R(B | metallothionein zinc sensitivity MTT assay
| 7-b | 13 |
13:15$B!A(B 13:30 | L12 | $BS.F}F0J*:YK&$N@8M}5!G=JQ2=$rMxMQ$7$?O;2A%/%m%`$N8!=P(B
($BNk9b@l(B) $B!{J]:d(B $B9@>O(B$B!&(B ($B@5(B)$B>.@n(B $B0!4u;R(B | MTT assay LDH cytotoxicity assay chromium hexavalent
| 7-b | 15 |
13:30$B!A(B 13:45 | L13 | $BF0J*:YK&$NG]M\7O$rMxMQ$7$?;02A%/%m%`$N8!=P(B
($BNk9b@l(B) $B!{EDCf(B $BM:;N(B$B!&(B ($B@5(B)$B>.@n(B $B0!4u;R(B | chromium trivalent MTT assay LDH cytotoxicity assay
| 7-b | 16 |
13:45$B!A(B 14:00 | L14 | ATP$B9g@.9ZAG$N(BFo$B$N@:@=$H(Bb$B%5%V%f%K%C%H93BN$N7k9g@-$NI>2A(B
($B1'It9b@l(B) $B!{NSED(B $BD>$B!&(B $B<<(B $BM3M|2B(B$B!&(B $BJ?ED(B $B$B!&(B $BIY;3(B $BBY;j(B$B!&(B $B$B!&(B $B;0N1(B $B5,M@(B | membrane protein monoclonal antibody. FoF1ATP synthase
| 7-b | 61 |
14:00$B!A(B 14:15 | L15 | 10$BNLBN(Bc$B%5%V%f%K%C%H$rMQ$$$?(BATP$B9g@.9ZAG$N2sE>$N@)8f(B
($B1'It9b@l(B) $B!{F#Ln(B $B0lLp(B$B!&(B $BIY;3(B $BBY;j(B$B!&(B $BE{0f(B $B2mH~(B$B!&(B $B;0N1(B $B5,M@(B | Molecular motor rotation FoF1 ATP synthase
| 7-b | 64 |
(14:15$B!A(B15:30) ($B:BD9(B $B5HED(B $B7r!&1|K\(B $BNIGn(B) |
14:15$B!A(B 14:30 | L16 | F1-ATPase$B$N(BATP$B2C?eJ,2r3h@-$N(BpH$B0MB8@-$H?(G^It0L$X$NJQ0[$N1F6A(B
($B1'It9b@l(B) $B!{;{2,(B $BM44u(B$B!&(B $B$B!&(B $B6b;R(B $BF7(B$B!&(B $BEgB^(B $B>!Lo(B$B!&(B $B;0N1(B $B5,M@(B | F1-ATPase ATP hydrolysis catalytic site
| 7-b | 65 |
14:30$B!A(B 14:45 | L17 | $B%J%H%j%&%`M"Aw@-(BATP$B9g@.9ZAG$N(BATP$B9g@.3h@-$H%A%c%M%k$N2r@O(B
($B1'It9b@l(B) $B!{IY;3(B $BBY;j(B$B!&(B ($BEl9)Bg(B) $B:4F#(B $B9($B!&(B ($BAaBg(B) $BNkLZ(B $B=S<#(B$B!&(B ($B5~;:Bg(B) $B5HED(B $B8-1&(B$B!&(B ($B1'It9b@l(B) $B;0N1(B $B5,M@(B | Sodium transport ATP synthase ion channel
| 7-b | 66 |
14:45$B!A(B 15:00 | L18 | ATP$B9g@.9ZAG$N(BFo$B$NJQ0[$K$h$k(BH+$BM"Aw3h@-$H%$%*%sM"Aw5!9=$N2r@O(B
($B1'It9b@l(B) $B!{$B!&(B ($BEl9)Bg(B) $B:4F#(B $B9($B!&(B ($BAaBg(B) $BNkLZ(B $B=S<#(B$B!&(B ($B5~;:Bg(B) $B5HED(B $B8-1&(B$B!&(B ($B1'It9b@l(B) $B>>@>(B $BBs:H(B$B!&(B $B_@ED(B $B9/J?(B$B!&(B $B;0N1(B $B5,M@(B | Proton transport ATP synthase
| 7-b | 68 |
15:00$B!A(B 15:15 | L19 | $B3$AtM3MhB?E|$K$h$k93;@2=:nMQ$N8!F$(B
($BNk9b@l(B) $B!{>.yu(B $B$R$JG5(B$B!&(B ($B9>Fn2=9)(B) $B@>1:(B $B70(B$B!&(B ($BNk9b@l(B) ($B@5(B)$B>.@n(B $B0!4u;R(B | antioxidant polysaccharide SOD
| 7-b | 80 |
15:15$B!A(B 15:30 | L20 | $B:YK&4V$N:YK&Kl>e0!1t%H%i%s%9%]!<%?!<$NH/8=NLHf3S$H0!1t$K$h$kA}?#M^@)$H$N4XO"(B
($BNk9b@l(B) $B!{4dED(B $B2L5W(B$B!&(B ($B@5(B)$B>.@n(B $B0!4u;R(B | ZIP zinc proliferation
| 7-d | 14 |